528 results about "Organelle" patented technology

Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. Thelower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and / or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.

The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analyses, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.

The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analysis. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analysis, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.

A device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest. The device includes a number of projections for penetrating a body surface, with the number of projections being selected to produce a desired response, and the number being at least 500. A spacing between projections is also at least partially determined based on an arrangement of the targets within the body.

This invention relates to reagent comprising: any one of cells, viral particles, organelles, parasites, cells comprising organelles, cells comprising viral particles, cells comprising parasites, cells comprising bacterial cells and any combination thereof, the cells, viral particles, organelles or parasites comprising at least one nucleic acid sequence serving as an internal control (IC) target for nucleic acid testing (NAT) assay; wherein the reagent is suitable to be added to a test sample undergoing sample preparation to release, concentrate and / or purify nucleic acids and amplification and / or detection of nucleic acids so as to be used to verify: (i) the efficiency of sample preparation; and (ii) the efficiency of nucleic acid amplification and / or detection. The present invention also relates to a method to verify or validate the preparation and amplification and / or detection of a nucleic acid target sequence in a sample spiked with a reagent of the present invention.